Nordic Group B.V. Through Its Subsidiary Amring Pharmaceuticals Inc., Appoints Ophthalmology Innovator, Eric D. Donnenfeld, MD as Medical Advisory Board Chair
Nordic Pharma Completes Acquisition of Visant Medical
Enforcement Report - Week of June 21, 2023
BERWYN, Pa.--(BUSINESS WIRE)--Amring Pharmaceuticals Inc. (Amring), a niche generic and brand pharmaceutical company, announced today it has joined The End Drug Shortages Alliance (Alliance), a new coalition of diverse stakeholders to address drug shortages in the United States. Alliance provides a forum for key stakeholders to take strategic aim at one of health care’s more pressing and enduring issues, drug shortages that disrupt patient care.
BERWYN, Pa.--(BUSINESS WIRE)--Amring Pharmaceuticals Inc. (Amring), a niche generic and brand pharmaceutical company, announced today that it has received FDA approval for generic Timolol Maleate Ophthalmic Solution, USP 0.5%, 60 pack of 0.3mL unit dose vials (AT3 rated generic equivalent of Timoptic® in Ocudose®) and has begun commercialization activities.
BERWYN, Pa.--(BUSINESS WIRE)--Amring Pharmaceuticals Inc. (Amring), a niche generic and brand pharmaceutical company, announced today that it has received FDA approval for generic Lamotrigine ODT, USP (25mg, 50mg, 100mg and 200mg) available in bottles of 30 tablets (AB rated generic equivalent of Lamictal®), and has begun commercialization activities.
Amring Pharms' Generic Lamotrigine Receives Approval in the U.S.
BERWYN, Pa.--(BUSINESS WIRE)--Amzell,nB.V., a specialty pharmaceutical development company based in The nNetherlands, and Amring Pharmaceuticals Inc. (Amring), a niche brand andngeneric pharmaceutical company based in Berwyn, PA, announced today nthat their lead product in the collaboration, AMZ002, has entered Phase nIII Clinical Trial in the U.S. for treatment of infantile epileptic ndisease. AMZ002, a purified synthetic polypeptide, offers an alternativento existing FDA-approved treatment for epileptic seizures. This productnreceived both Rare Pediatric Disease and Orphan-Drug Designations.
BERWYN, Pa.--(BUSINESS WIRE)--Amzell, B.V., a specialty pharmaceutical development company based in The Netherlands, and Amring Pharmaceuticals Inc. (Amring), a niche brand and generic pharmaceutical company based in Berwyn, PA, announced today that their lead product in the collaboration, AMZ002, has entered Phase III Clinical Trial in the U.S. for treatment of infantile epileptic disease. AMZ002, a purified synthetic polypeptide, offers an alternative to existing FDA-approved treatment for epileptic seizures. This product received both Rare Pediatric Disease and Orphan-Drug Designations.
BERWYN, Pa.--(BUSINESS WIRE)--Amring Pharmaceuticals Inc. (Amring), a niche generic and brand pharmaceutical company, announced today that on August 23, 2021 it entered into a license agreement with Pierre Fabre Farma de Mexico, S.A. de C.V. (Pierre Fabre), a subsidiary of the Pierre Fabre group which distribute products in over 100 countries around the world. Under the agreement, Amring granted to Pierre Fabre an exclusive royalty-bearing license to exploit and commercialize LYSTEDA (tranexamic acid), a first-in-class, non-hormonal therapy indicated specifically for treatment of women with cyclic heavy menstrual bleeding (HMB) in Mexico.